Search / Trial NCT00002248

A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients

Launched by UNIVAX BIOLOGICS INC · Aug 30, 2001

Trial Information

Current as of December 26, 2024

Completed

Keywords

Antidiarrheals Cryptosporidiosis Diarrhea Acquired Immunodeficiency Syndrome Cryptosporidium Immunization, Passive

ClinConnect Summary

Forty patients are randomized to receive either BACI or placebo (bovine colostrum from non-immunized cattle) for 1 week. The double-blind portion of the study will be followed by an open-label phase in which all 40 patients receive BACI for 1 week.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • Antidiarrheal compounds (if dose remains stable).
  • Zidovudine (AZT), dideoxyinosine (ddI), dideoxycytidine (ddC), or alternative HIV therapy (provided dose was stable for at least 4 weeks prior to study entry).
  • Patients must have:
  • AIDS.
  • Cryptosporidium parvum enteritis.
  • Chronic diarrhea.
  • Life expectancy of at least 4 weeks.
  • Ability to tolerate food by mouth.
  • Ability to take the histamine H2-receptor antagonist famotidine (Pepcid).
  • Prior Medication:
  • Allowed:
  • Antidiarrheal compounds (provided dose has remained stable in the 7 days prior to study entry).
  • Zidovudine (AZT), dideoxyinosine (ddI), dideoxycytidine (ddC), or alternative HIV therapy (provided dose has remained stable for at least 4 weeks prior to study entry).
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following symptoms or conditions are excluded:
  • Concurrent unresolved clinical infections with enteric pathogens other than C. parvum (e.g., rotavirus, Salmonella, Shigella, Campylobacter, Giardia, C. difficile toxin, Yersinia, amebiasis, MAI, CMV, Microsporida) as determined by history or routine microbiology screening.
  • Other acute infections or concurrent immediately life-threatening medical crisis other than cryptosporidiosis.
  • Grossly bloody diarrhea.
  • Known allergy to milk or milk products (other than lactose intolerance).
  • Prior Medication:
  • Excluded:
  • Other experimental therapy (e.g., macrolide antibiotics, paromomycin) within 30 days prior to study entry.

About Univax Biologics Inc

Univax Biologics Inc. is a leading biopharmaceutical company dedicated to the research, development, and commercialization of innovative vaccine therapies and biologics. With a focus on addressing unmet medical needs, Univax leverages cutting-edge science and technology to create effective solutions for infectious diseases and immune-related conditions. The company is committed to rigorous clinical trial protocols, ensuring the safety and efficacy of its products while adhering to the highest regulatory standards. Through collaboration with academic institutions and industry partners, Univax aims to advance public health and improve patient outcomes globally.

Locations

New York, New York, United States

Atlanta, Georgia, United States

San Francisco, California, United States

Boston, Massachusetts, United States

Los Angeles, California, United States

Boston, Massachusetts, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials